Comparative Study of Both Versions of an Immunoassay Commercialized for Therapeutic Drug Monitoring of Adalimumab in Rheumatoid Arthritis

Autor:	Lara Valor, José Rosas, Inmaculada de la Torre, Francisca Llinares-Tello, Senabre Jm, Xavier Barber
Rok vydání:	2014
Předmět:	medicine.medical_specialty medicine.diagnostic_test business.industry General Medicine medicine.disease Therapeutic drug monitoring Internal medicine Immunoassay Rheumatoid arthritis Immunology medicine Adalimumab In patient business medicine.drug
Zdroj:	Reumatología Clínica (English Edition). 10:105-108
ISSN:	2173-5743
DOI:	10.1016/j.reumae.2013.12.006
Popis:	Objective To describe the results of the comparative study between both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab (ADA) in rheumatoid arthritis (AR). Material and methods 140 samples of patients with RA treated with ADA 40 mg every 14 days were analyzed by both versions of the test (V1 or previous and V2 or updated). Results A good correlation was obtained by both versions. In general V2 provides higher results of ADA's concentration than V1 and presents greater precision in the range of concentrations for clinical decisions, adjusting for the real concentration of the drug in blood. In addition, V2 allows for complete automation, which simplifies the analysis and reduces significantly the variability. Conclusion ADA's monitoring with the updated version demonstrated to have technical significant advantages, constituting a more practical tool for therapeutic decisions in patients with RA.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c7202ced8720bfa61b194b1240cc021c https://doi.org/10.1016/j.reumae.2013.12.006 Zobrazit plný text záznamu Full Text from ScienceDirect